UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000032448 |
|---|---|
| Receipt number | R000036991 |
| Scientific Title | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome |
| Date of disclosure of the study information | 2018/05/01 |
| Last modified on | 2022/03/11 14:17:15 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome
Acronym
CARDINAL
Scientific Title
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome
Scientific Title:Acronym
CARDINAL
Region
| Japan | North America | Australia |
| Europe |
Condition
Condition
Alport Syndrome
Classification by specialty
| Nephrology | Pediatrics | Urology |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
- To assess the change from baseline in estimated glomerular filtration rate (eGFR) in bardoxolone methyl-treated patients relative to placebo after 48 weeks of treatment.
- To assess the safety of bardoxolone methyl relative to placebo after 48 weeks of treatment.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The change from baseline in eGFR in bardoxolone methyl-treated patients relative to placebo at Week 48
Key secondary outcomes
The change from baseline in eGFR in bardoxolone methyl-treated patients relative to placebo at Week 52 following a 4-week drug treatment withdrawal period.
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Drug: Bardoxolone Methyl
Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status. Dosing period is up to 2 years.
Interventions/Control_2
Drug: Placebo Oral Capsule
Capsule containing an inert placebo is administrated up to 2 years.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 12 | years-old | <= |
Age-upper limit
| 70 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1. Male and female patients from the age of 12 to 70 upon study consent
2. Diagnosis of Alport syndrome by genetic testing (documented mutation in a gene associated with Alport syndrome, including COL4A3, COL4A4, or COL4A5) or histologic assessment using electron microscopy
3. Screening eGFR (average of Screen A and Screen B eGFR values) is from 30 to 90 mL/min/1.73 m2. The two eGFR values collected at Screen A and Screen B visits used to determine eligibility must have a percent difference of 25% and under
4. Albumin to creatinine ratio (ACR) is 3500 mg/g and under at Screen B visit. Up to 50% of patients in the Phase 2 cohort and approximately 40% of patients enrolled in the Phase 3 cohort can have ACR of 301 to 3500 mg/g. Once enrollment of these patients is complete, the ACR inclusion criterion is 300 mg/g and under.
5. Patients receiving an angiotensin-converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB) should be receiving the maximally tolerated labeled daily dose for at least 6 weeks prior to the Screen A visit. The dosage of ACE inhibitor and/or ARB should remain the same throughout the remainder of the study. Patients not currently taking an ACE inhibitor and/or ARB because they are not indicated or because of a medical contraindication may be eligible provided the patient has not taken an ACE inhibitor and/or ARB at least 8 weeks prior to the Screen A visit.
6. Adequate bone marrow reserve and organ function at the Screen A visit as follows:
a. Hematologic: Absolute neutrophil count > 1500/microliter, platelets > 100000/microliter, hemoglobin of 9 g/dL and over
b. Hepatic: Total bilirubin (TBL) of 1.5X the upper limit of normal (ULN) and under, ALT and AST of 1.5X ULN and under
7. Able to swallow capsules
8. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
9. Evidence of a personally signed and dated informed consent document
Key exclusion criteria
1. Prior exposure to bardoxolone methyl
2. Ongoing chronic hemodialysis or peritoneal dialysis therapy
3. Renal transplant recipient
4. B-type natriuretic peptide (BNP) level > 200 pg/mL at Screen A visit
5. Uncontrolled diabetes (HbA1c > 11.0%) at Screen A visit
6. Acute dialysis or acute kidney injury within 12 weeks prior to Screen A visit or during Screening
7. Serum albumin < 3 g/dL at Screen A visit
8. History of clinically significant left-sided heart disease and/or clinically significant cardiac disease
9. Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) > 160 mm Hg or sitting diastolic BP > 100 mm Hg at Screen A visit after a period of rest
10. Systolic BP < 90 mm Hg at Screen A visit after a period of rest
11. History of malignancy within 5 years prior to Screen A visit, with the exception of localized skin or cervical carcinomas
12. Systemic immunosuppression for more than 2 weeks, cumulatively, within the 12 weeks prior to randomization or anticipated need for immunosuppression during the study
13. Untreated or uncontrolled active bacterial, fungal, or viral infection
14. Participation in other interventional clinical studies within 30 days prior to Day 1
15. Unwilling to practice acceptable methods of birth control (both males who have partners of child-bearing potential and females of childbearing potential) during Screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested
16. Women who are pregnant or breastfeeding
17. Known hypersensitivity to any component of the study drug
Target sample size
180
Research contact person
Name of lead principal investigator
| 1st name | Colin |
| Middle name | |
| Last name | Meyer |
Organization
Reata Pharmaceuticals, Inc
Division name
Product Development
Zip code
TX 75063
Address
2801 Gateway Drive, Suite 150 Irving, Texas, USA
TEL
+1-972-865-2202
Colin.Meyer@reatapharma.com
Public contact
Name of contact person
| 1st name | Yukiko |
| Middle name | |
| Last name | Hagihara |
Organization
Labcorp Development Japan K.K.
Division name
Clinical Development Services
Zip code
104-6108
Address
Harumi Triton Square Office Tower Y 8F 1-8-11, Harumi, Cho-ku, Tokyo
TEL
03-6837-9500
Homepage URL
Yukiko.Hagihara@labcorp.com
Sponsor or person
Institute
Reata Pharmaceuticals, Inc
Institute
Department
Personal name
Funding Source
Organization
Reata Pharmaceuticals, Inc
Organization
Division
Category of Funding Organization
Outside Japan
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Japan Community Health care Organization Sendai Hospital Institutional Review Board
Address
3-16-1 Tsutsumimachi, Aoba-ku, Sendai, Miyagi
Tel
022-275-3111
keiko-yoshino@j-smo.com
Secondary IDs
Secondary IDs
YES
Study ID_1
NCT03019185
Org. issuing International ID_1
ClinicalTrials.gov
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
独立行政法人地域医療機能推進機構 仙台病院（宮城県）
埼玉県立小児医療センター（埼玉県）
順天堂大学医学部附属順天堂医院（東京都）
東京都立小児総合医療センター（東京都）
聖マリアンナ医科大学病院（神奈川県）
名古屋第二赤十字病院（愛知県）
独立行政法人地域医療機能推進機構 中京病院（愛知県）
公益財団法人 田附興風会 医学研究所 北野病院（大阪府）
神戸大学医学部附属病院（兵庫県）
佐賀大学医学部附属病院（佐賀県）
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 05 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004395-22/results
Number of participants that the trial has enrolled
187
Results
Results date posted
| 2019 | Year | 05 | Month | 11 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Main results already published
Date of protocol fixation
| 2016 | Year | 11 | Month | 15 | Day |
Date of IRB
| 2017 | Year | 11 | Month | 06 | Day |
Anticipated trial start date
| 2018 | Year | 05 | Month | 01 | Day |
Last follow-up date
| 2020 | Year | 11 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
In Japan, a double-blind, randomized, and placebo-controlled study is under way, which is Phase 3 portion.
Management information
Registered date
| 2018 | Year | 05 | Month | 01 | Day |
Last modified on
| 2022 | Year | 03 | Month | 11 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036991
